CSRD is one of the first pharmaceutical companies focused on the mitochondrially addressed antioxidants and sirtuins. Mitochondrially addressed antioxidants are new class of highly bioavailable pharmaceuticals which are shown to be safe and effective in human trials where current antioxidant therapies are of lack of efficacy. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases, including Type 2 Diabetes, various types of cancer and osteoporosis; as well as neurodegenerative, cardiovascular, inflammatory, and mitochondrial diseases.
Founded in 1995, is developing small molecule drugs that target the mitochondria and sirtuins, a recently discovered family of seven enzymes associated with the aging process. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas.
CSRD Focuses on the molecular regulation of mitochondrial functions during aging and age-related disease. Our goal is to investigate how pathways that control aging, such as ubiquinone, impact mitochondrial fuel utilization, bioenergetics and signaling. To achieve these objectives, we take a multidisciplinary approach that employs biochemical, cellular, and human modeling experiments to systematically dissect the mitochondrial pathways of interest.